Digilab - Life-Sciences Instruments, Software and Consumables

Digilab designs, develops, manufactures and markets scientific instruments, software and consumables for the global life-sciences research markets. These tools are comprised of applications, differentiated products and services.

In addition to being broadly appreciated in the life and analytical sciences research market, Digilab’s products also serve the healthcare, manufacturing, and safety and security markets. The company currently offers solutions to more than 2,000 customers from across the globe.

MODULAR SPECTOMETERS

Digilab originated in 1969 when pioneering work for the US government led to the development and manufacture of the first commercial Fourier-Transform Infra-Red (FT-IR) spectrometer.

In 1978, Digilab was acquired by Bio-Rad Laboratories and in October 2001, a new Digilab was launched by Sidney Braginsky, CEO of Atropos Technologies and former president and COO of Olympus America,

In April 2003, Digilab offered the broadest wavelength range of molecular spectroscopy solutions as the exclusive distributor of Hitachi's UV-Vis and fluorescence life-science products in North America and Europe. This partnership took Digilab’s installed instrument base from 5,000 units to more than 15,000 units.

PEPTIDOMICS SERVICES

Digilab provides interdisciplinary solutions for an earlier and more precise definition of diseases and for the discovery and identification of endogenous peptides, which may serve as biomarkers or as a starting point for the development of novel drugs.

Digilab’s peptidomics services may aid in:

• Discovery of biomarkers for a differential diagnosis and disease progression
• Profiling drug effects
• Discovery of biomarkers that predict and monitor response to a defined therapeutic principle
• Discovery and validation of biologically active peptides and drug leads
• Discovery and characterization of drug targets
• Characterization of biological models from cells, tissues or knockout animals

ACQUISITIONS AND PARTNERSHIPS

Since February 2006, Digilab has made a number of significant acquisitions to broad and deepen its offerings:

• Acquisition of Genomic Solutions and MAIA scientific businesses from Harvard Biosciences (HBIO): broadened Digilab’s global footprint in both the life-sciences research pre-analytics market and strengthened its commitment to provide downstream systems and solutions with broad application in clinical diagnostics
• Acquisition of Biovision: provided core competence, products and services for biomarker and target discovery, validation and development
• Acquisition of Spectracode: provided core competence and products in high-growth applications which require the versatility and ease of use of raman molecular spectroscopy; SpectraCode's close affiliation with Purdue University is an important asset in Digilab's goal to commercialize portable and handset raman spectroscopy systems
• Partnership with Boehringher Ingelheim Microparts (BImP): product development relationship and an exclusive distribution agreement; BImP is recognized by the global pharmaceutical and diagnostics industries as being a leading design, development and manufacturing firm in the fields of micro fluidics and Micro Systems Technologies (MST)